These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 19374459)

  • 41. Review of donepezil, rivastigmine, galantamine and memantine for the treatment of dementia in Alzheimer's disease in adults with Down syndrome: implications for the intellectual disability population.
    Prasher VP
    Int J Geriatr Psychiatry; 2004 Jun; 19(6):509-15. PubMed ID: 15211527
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Caregiver Preference and Treatment Compliance in Patients with Mild-to-Moderate Alzheimer's Disease in South Korea: RECAP Study Results.
    Lee KJ; Cho SJ; Kim BC; Park M; Lee JH
    Adv Ther; 2017 Feb; 34(2):481-494. PubMed ID: 28000168
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Treatment strategies for the behavioral symptoms of Alzheimer's disease: focus on early pharmacologic intervention.
    Beier MT
    Pharmacotherapy; 2007 Mar; 27(3):399-411. PubMed ID: 17316151
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effective pharmacologic management of Alzheimer's disease.
    Farlow MR; Cummings JL
    Am J Med; 2007 May; 120(5):388-97. PubMed ID: 17466645
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cost-utility analysis of memantine extended release added to cholinesterase inhibitors compared to cholinesterase inhibitor monotherapy for the treatment of moderate-to-severe dementia of the Alzheimer's type in the US.
    Saint-Laurent Thibault C; Özer Stillman I; Chen S; Getsios D; Proskorovsky I; Hernandez L; Dixit S
    J Med Econ; 2015; 18(11):930-43. PubMed ID: 26086535
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Drug delivery strategies for Alzheimer's disease treatment.
    Di Stefano A; Iannitelli A; Laserra S; Sozio P
    Expert Opin Drug Deliv; 2011 May; 8(5):581-603. PubMed ID: 21391862
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of antidementia drugs and risk of pneumonia in older persons with Alzheimer's disease.
    Lampela P; Tolppanen AM; Tanskanen A; Tiihonen J; Lavikainen P; Hartikainen S; Taipale H
    Ann Med; 2017 May; 49(3):230-239. PubMed ID: 27786552
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparative safety and effectiveness of cholinesterase inhibitors and memantine for Alzheimer's disease: a network meta-analysis of 41 randomized controlled trials.
    Dou KX; Tan MS; Tan CC; Cao XP; Hou XH; Guo QH; Tan L; Mok V; Yu JT
    Alzheimers Res Ther; 2018 Dec; 10(1):126. PubMed ID: 30591071
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical pharmacokinetics and pharmacodynamics of cholinesterase inhibitors.
    Jann MW; Shirley KL; Small GW
    Clin Pharmacokinet; 2002; 41(10):719-39. PubMed ID: 12162759
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Therapeutic effects of drug switching between acetylcholinesterase inhibitors in patients with Alzheimer's disease.
    Ohta Y; Darwish M; Hishikawa N; Yamashita T; Sato K; Takemoto M; Abe K
    Geriatr Gerontol Int; 2017 Nov; 17(11):1843-1848. PubMed ID: 28060449
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Predictors of adherence among Alzheimer's disease patients receiving oral therapy.
    Borah B; Sacco P; Zarotsky V
    Curr Med Res Opin; 2010 Aug; 26(8):1957-65. PubMed ID: 20569067
    [TBL] [Abstract][Full Text] [Related]  

  • 52. A Systematic Review on Donepezil-based Derivatives as Potential Cholinesterase Inhibitors for Alzheimer's Disease.
    Korabecny J; Spilovska K; Mezeiova E; Benek O; Juza R; Kaping D; Soukup O
    Curr Med Chem; 2019; 26(30):5625-5648. PubMed ID: 29768996
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association between Anti-Dementia Treatment Persistence and Daily Dosage of the First Prescription: A Retrospective Analysis in Neuropsychiatric Practices in Germany.
    Bohlken J; Jacob L; Kostev K
    J Alzheimers Dis; 2017; 58(1):37-44. PubMed ID: 28372337
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Rationale for combination therapy with galantamine and memantine in Alzheimer's disease.
    Grossberg GT; Edwards KR; Zhao Q
    J Clin Pharmacol; 2006 Jul; 46(7 Suppl 1):17S-26S. PubMed ID: 16809811
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Review of the validated HPLC and LC-MS/MS methods for determination of drugs used in clinical practice for Alzheimer's disease.
    Ponnayyan Sulochana S; Sharma K; Mullangi R; Sukumaran SK
    Biomed Chromatogr; 2014 Nov; 28(11):1431-90. PubMed ID: 24515838
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cholinesterase as a Target for Drug Development in Alzheimer's Disease.
    Sharma P; Tripathi MK; Shrivastava SK
    Methods Mol Biol; 2020; 2089():257-286. PubMed ID: 31773661
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Molecular pathogenesis and development of disease-modifying drugs for Alzheimer's disease].
    Takeda M
    Seishin Shinkeigaku Zasshi; 2013; 115(1):32-40. PubMed ID: 23691792
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [Current approaches to optimize treatment of dementia and Alzheimer's disease].
    Kolykhalov IV
    Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(6):87-92. PubMed ID: 28635795
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.